| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CGRP |
| Uniprot No | P06881 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 83-119aa |
| 氨基酸序列 | ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF |
| 预测分子量 | 35.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CGRP(降钙素基因相关肽)重组蛋白的3篇代表性文献及其摘要内容概括：
1. **文献名称**：*CGRP as the target of new migraine therapies — successful translation from bench to clinic*
**作者**：Edvinsson L, Hargreaves R
**摘要**：综述了CGRP在偏头痛病理机制中的核心作用，探讨了针对CGRP或其受体的重组蛋白类药物(如单克隆抗体和小分子拮抗剂)的研发进展及临床试验结果，证实其能有效减少偏头痛发作频率。
2. **文献名称**：*Safety and efficacy of a monoclonal antibody against calcitonin gene-related peptide for migraine prevention: a randomised controlled trial*
**作者**：Dodick DW et al.
**摘要**：报道了一种CGRP重组单克隆抗体的III期临床试验结果，证明该药物可显著降低慢性偏头痛患者的发作次数，且安全性良好，为CGRP靶向治疗提供了临床证据。
3. **文献名称**：*Expression and characterization of recombinant human CGRP in Escherichia coli*
**作者**：Huang Y et al.
**摘要**：研究利用大肠杆菌表达系统高效生产重组人CGRP蛋白，通过优化表达条件与纯化工艺获得高纯度产物，并验证其体外生物活性(如血管舒张作用)，为大规模制备CGRP相关药物奠定基础。
---
**注**：CGRP相关研究多集中于其受体拮抗剂或单克隆抗体，直接针对重组CGRP蛋白的研究相对较少，上述文献覆盖机制、治疗应用及重组生产技术。
**Background of Recombinant CGRP Protein**
Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide widely distributed in the central and peripheral nervous systems. It exists in two isoforms, α-CGRP and β-CGRP, with α-CGRP primarily expressed in sensory neurons and β-CGRP in enteric neurons. CGRP plays critical roles in vasodilation, pain modulation, inflammation, and neurogenic responses. Its involvement in migraine pathophysiology, particularly through vasodilation and nociceptive signaling, has made it a key therapeutic target.
Recombinant CGRP protein is produced via genetic engineering, typically using bacterial (e.g., *E. coli*) or mammalian expression systems. This technology enables large-scale production of high-purity CGRP for research and clinical applications. Recombinant CGRP retains biological activity, allowing scientists to study its receptor interactions (e.g., with CLR/RAMP1 complexes) and downstream pathways (e.g., cAMP signaling). It is also used to develop antibodies or small-molecule inhibitors, such as CGRP receptor antagonists (gepants) and monoclonal antibodies (e.g., erenumab), which are FDA-approved for migraine prevention.
Beyond migraines, recombinant CGRP is investigated in cardiovascular diseases, wound healing, and bone metabolism due to its vasoprotective and trophic effects. However, challenges remain, including optimizing stability, delivery methods, and minimizing off-target effects. Advances in protein engineering, such as site-specific PEGylation or fusion proteins, aim to enhance its therapeutic potential.
In summary, recombinant CGRP protein serves as a vital tool for understanding neuropeptide biology and developing targeted therapies, reflecting the intersection of neuroscience, molecular biology, and clinical medicine.
×
